Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

384 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, Graeven U, Lokich J, Madajewicz S, Maroun JA, Marshall JL, Mitchell EP, Perez-Manga G, Rougier P, Schmiegel W, Schoelmerich J, Sobrero A, Schilsky RL. Van Cutsem E, et al. Among authors: schilsky rl. Br J Cancer. 2004 Mar 22;90(6):1190-7. doi: 10.1038/sj.bjc.6601676. Br J Cancer. 2004. PMID: 15026800 Free PMC article. Clinical Trial.
Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer.
Mani S, Hochster H, Beck T, Chevlen EM, O'Rourke MA, Weaver CH, Bell WN, White R, McGuirt C, Levin J, Hohneker J, Schilsky RL, Lokich J. Mani S, et al. Among authors: schilsky rl. J Clin Oncol. 2000 Aug;18(15):2894-901. doi: 10.1200/JCO.2000.18.15.2894. J Clin Oncol. 2000. PMID: 10920138 Clinical Trial.
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S, Vogelzang NJ, Bertucci D, Stadler WM, Schilsky RL, Ratain MJ. Mani S, et al. Among authors: schilsky rl. Cancer. 2001 Sep 15;92(6):1567-76. doi: 10.1002/1097-0142(20010915)92:6<1567::aid-cncr1483>3.0.co;2-l. Cancer. 2001. PMID: 11745236 Clinical Trial.
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Pérez-Manga G, Rosso R, Rougier P, Schilsky RL; Capecitabine Colorectal Cancer Study Group. Cassidy J, et al. Among authors: schilsky rl. Ann Oncol. 2002 Apr;13(4):566-75. doi: 10.1093/annonc/mdf089. Ann Oncol. 2002. PMID: 12056707 Free article. Clinical Trial.
Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.
Goey KKH, Sørbye H, Glimelius B, Adams RA, André T, Arnold D, Berlin JD, Bodoky G, de Gramont A, Díaz-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman M. Goey KKH, et al. Among authors: schilsky rl. Eur J Cancer. 2018 Sep;100:35-45. doi: 10.1016/j.ejca.2018.05.010. Epub 2018 Jun 22. Eur J Cancer. 2018. PMID: 29936065
384 results